Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Cardiovascular Health, Breast Cancer, Br...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study focuses on male and female patients being treated for breast cancer that is positive for the HER2 receptor which requires special treatments targeting that receptor. The problem is that these treatments, while effective for the cancer, can sometimes harm the heart. Because of this, patients have to undergo heart tests every three months during treatment, even if they have no history of heart disease or feel fine. The guidelines for these regular heart tests were established decades ago when these treatments were first introduced, but research shows that most of these tests don't actually change the treatment plan. This suggests that many patients are going through unnecessary tests, which can cause stress, delay treatments, and increase healthcare costs. To address this, the researchers propose a new study with 300 patients with HER2 positive breast cancer to test a more personalized approach to cardiac surveillance. Participants will be classified based on their risk of heart problems: low or intermediate. Instead of testing every patient every three months, those in the intermediate group will be tested every 4 months, and those in the low-risk group will be tested every 6 months. The researchers will compare this new approach to the current system to see if fewer tests are just as safe and effective. The researchers will measure heart health, how well cancer treatments are completed, and how patients feel about having fewer tests. If this new approach works, it could save money and reduce the burden on female patients without risking their health.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: Single

Interventions / Regimen

  • Diagnostic Test: Intervention - Low Risk Group OR Intermediate Risk Group — Participants will be randomized to judicious imaging (decreased imaging frequency based on HF risk category) or SOC (imaging every 3 months). Participants who do not have any HF risk factors will be categorized as low risk, while participants with at least one risk factor will be categorized as intermediate risk for HF. Low Risk (zero risk factors): imaging before cycles 1 and 9 of HER2-TT (i.e., at baseline and near the halfway mark, corresponding to 2 fewer studies than SOC in Year 1), then after the end of HER2TT. This translates to imaging every 6 months for uninterrupted adjuvant HER2TT. Intermediate Risk (any risk factors): imaging before cycles 1, 6, and 12 of HER2-TT (i.e., at baseline and near the 1/3 and 2/3 marks, corresponding to 1 fewer study than SOC in Year 1), then at end of HER2TT. This translates to imaging every 4 months for uninterrupted adjuvant HER2TT.

Primary Outcomes

  • Clinically overt heart failure (From enrollment to <100days after end of treatment)
  • Premature HER2TT discontinuation (From enrollment to <100days after end of treatment)
  • Patient-reported outcome measures (PROMS) of anxiety/depression, stress, and treatment burden (From enrollment to <100 days after end of treatment)
  • Asymptomatic cardiotoxicity at end of HER2TT (From enrollment to <100 days after the end of treatment)
  • Time to complete HER2TT (From enrollment to <100 days after the end of treatment)
  • Total number of cardiac imaging tests during HER2TT (From enrollment to <100 days after the end of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-22
Completion: 2033-06
Eligibility
Age: 18 Years – 79 Years
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Women's College Hospital
Collaborators: University Health Network, Toronto
Contact Information
Study Contact:
Husam Abdel-Qadir, MD, PhD, FRCPC
416-323-7723
husam.abdel-qadir@wchospital.ca
Priyancee Sabhaya, MSc
437-522-6441
Priyancee.Sabhaya2@uhn.ca
Toronto General Hospital
Husam Abdel-Qadir, MD, PhD
Toronto General Hospital
Interventions
  • Diagnostic Test: Intervention - Low Risk Group OR Intermediate Risk Group — Participants will be randomized to judicious imaging (decreased imaging frequency based on HF risk category) or SOC (imaging every 3 months). Participants who do not have any HF risk factors will be categorized as low risk, while participants with at least one risk factor will be categorized as intermediate risk for HF. Low Risk (zero risk factors): imaging before cycles 1 and 9 of HER2-TT (i.e., at baseline and near the halfway mark, corresponding to 2 fewer studies than SOC in Year 1), then after the end of HER2TT. This translates to imaging every 6 months for uninterrupted adjuvant HER2TT. Intermediate Risk (any risk factors): imaging before cycles 1, 6, and 12 of HER2-TT (i.e., at baseline and near the 1/3 and 2/3 marks, corresponding to 1 fewer study than SOC in Year 1), then at end of HER2TT. This translates to imaging every 4 months for uninterrupted adjuvant HER2TT.
Study Locations (1 sites)
Toronto General Hospital, Toronto, Ontario M5G 2C4 Canada
Eligibility Criteria
Inclusion Criteria: 1. Stage 1-3 breast cancer (BC). 2. Age 18-79 years. 3. HER-2 positive BC with planned HER2 targeted therapy (HER2TT) for curative intent. Exclusion Criteria: 1. Distant metastases detected clinically, radiographically, or histologically 2. Baseline echocardiogram images of insufficient quality for a quantitative assessment of left ventricular ejection fraction (LVEF) 3. Pre-existing cardiovascular disease, defined as: 1. Prior myocardial infarction (even if LVEF has normalized) 2. Prior heart failure (HF, including patients with preserved ejection fraction and normalized LVEF) 3. Baseline LVEF \<55% 4. Atrial fibrillation 5. Greater than moderate valvular disease (i.e., severe, or moderate-severe) 4. Cumulative anthracycline exposure ≥250mg/m2 before starting HER2TT 5. New York Heart Association Functional Class II, III or IV, or Eastern Cooperative Oncology Group score \>2\* 6. Symptoms potentially due to serious cardiac disease as per investigator's judgement\* \*Exclusion criterion adopted as they make clinical assessment less reliable to detect emergent HF.
Conditions HER2-positive, Unresectable, Locally Adv...
Phase PHASE2
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, single-arm, single-center, Phase II clinical study designed to assess the preliminary efficacy and safety of SKB264 Plus Inetetamab plus inetetamab for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer following progression on prior T-DXd therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SKB264 Plus Inetetamab — SKB264: 5 mg/kg administered on Day 1 of each 2-week cycle. Inetetamab: an initial loading dose of 6 mg/kg is administered, followed by subsequent maintenance doses of 4 mg/kg. Dosing occurs on Day 1 of each 2-week cycle.

Primary Outcomes

  • ORR by investigator (At baseline, at the time point of every 6 weeks, up to 1 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-09-30
Completion: 2029-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Hongxia Wang (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Juan Jin
15996290233
medjinjuan@126.com
Hongxia Wang
021-64175590
whx365@126.com
Hongxia Wang
13524491606
whx365@126.com
Fudan University Shanghai Cancer Center
Interventions
  • Drug: SKB264 Plus Inetetamab — SKB264: 5 mg/kg administered on Day 1 of each 2-week cycle. Inetetamab: an initial loading dose of 6 mg/kg is administered, followed by subsequent maintenance doses of 4 mg/kg. Dosing occurs on Day 1 of each 2-week cycle.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years, male or female. 2. Patients with histologically or cytologically confirmed breast cancer who meet the following criteria: 1. Unresectable locally advanced or metastatic breast cancer. 2. Pathologically confirmed HER2-positive breast cancer, regardless of hormone receptor (HR) status. HER2 positivity is defined as: IHC 3+, or IHC 2+ and FISH positive. 3. Prior treatment for unresectable locally advanced or metastatic disease must have included the following anti-HER2 therapies: trastuzumab deruxtecan (T-DXd) and trastuzumab (or a trastuzumab biosimilar). Patients who received T-DXd and trastuzumab (or a biosimilar) in the (neo)adjuvant setting and experienced recurrence or metastasis during or within 12 months of completing therapy are eligible. Additionally, prior treatment regimens must have included a taxane. 4. Documented disease progression or unacceptable toxicity after the last line of therapy for unresectable locally advanced or metastatic disease. 3. ECOG performance status of 0-2, with a life expectancy of \> 3 months. 4. At least one measurable target lesion according to RECIST v1.1 criteria. 5. Adequate organ and bone marrow function, as defined below: 1. Complete Blood Count: Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L; Platelets ≥ 75 × 10⁹/L; Hemoglobin ≥ 90 g/L. 2. Liver Function: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN); Total bilirubin (TBIL) ≤ 1.5 × ULN. For patients with liver metastases, ALT and AST ≤ 5.0 × ULN. 3. Renal Function: Serum creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula). 4. Coagulation Function: International Normalized Ratio (INR) ≤ 1.5 × ULN and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN. 5. Echocardiogram: Left Ventricular Ejection Fraction (LVEF) ≥ 50%. 6. 12-lead ECG: QT interval corrected by Fridericia's formula (QTcF) \< 470 ms for females and \< 450 ms for males. 6. Voluntarily agrees to participate in the study by signing the informed consent form (ICF), and is willing and able to comply with follow-up procedures. Exclusion Criteria: 1. Meningeal metastases confirmed by MRI or lumbar puncture. 2. Presence of spinal cord compression or clinically active central nervous system (CNS) metastases (defined as untreated or symptomatic metastases, or those requiring corticosteroids or anticonvulsants to control associated symptoms). Patients with previously treated brain metastases may be enrolled, provided they are clinically stable for at least 4 weeks, have no imaging evidence of progression, and at least 2 weeks have passed since the completion of brain radiotherapy and the discontinuation of corticosteroids or anticonvulsants for this indication. 3. Presence of third-space fluid accumulation (e.g., significant pleural effusion) that cannot be controlled by drainage or other methods. 4. Prior treatment with inetetamab or any TROP-2 antibody-drug conjugate (ADC). 5. Receipt of whole-brain radiotherapy, chemotherapy, biologic targeted therapy, immunotherapy, surgery, endocrine therapy, or other investigational drugs within 2 weeks prior to the first dose of study treatment. 6. Concurrent treatment with any other anti-cancer therapy. 7. Known history of hypersensitivity to any component of the study drugs. Permanent discontinuation of prior trastuzumab or its biosimilars due to any toxicity. 8. Severe or uncontrolled cardiac disease requiring treatment, including: 1. Congestive heart failure of New York Heart Association (NYHA) Class 3 or 4. 2. Unstable angina pectoris uncontrolled by medication. 3. Myocardial infarction within 6 months prior to the first dose of study treatment. 4. Severe arrhythmia requiring medical treatment (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia). 5. History of symptomatic congestive heart failure or a Left Ventricular Ejection Fraction (LVEF) \<40% during previous trastuzumab therapy. 9. Presence of any severe concomitant disease that, in the investigator's judgment, could jeopardize patient safety or interfere with study completion (e.g., uncontrolled severe diabetes, hypertension, autoimmune diseases), or any other condition deemed unsuitable for enrollment by the investigator. 10. Toxicity from prior anti-cancer therapy that has not resolved to NCI-CTCAE v5.0 Grade ≤1 or baseline level (with the exception of Grade 2 alopecia, pigmentation, or other toxicities such as simple laboratory abnormalities that the investigator considers to pose no safety risk). 11. History of other malignancies within the past 5 years, with the exception of curatively treated carcinoma in-situ, basal cell or squamous cell skin carcinoma, or papillary thyroid carcinoma after curative resection. 12. History of immunodeficiency, including a positive HIV test, active Hepatitis B or C, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation. 13. Known history of neurological or psychiatric disorders, including epilepsy or dementia. 14. Female patients of childbearing potential who are pregnant or breastfeeding. A negative serum pregnancy test is required within 7 days prior to randomization. Patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for 7 months after the last dose of study drug. 15. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study.
Conditions Breast Cancer
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter phase II trial planning to enroll 40 patients with primary triple-negative breast cancer (tumor size ≥2 cm, clinical lymph node stage cN0-3, M0). Participants will receive the combination therapy of Sac-TMT and KL-A167 during the neoadjuvant treatment phase. The study aims to evaluate the efficacy and safety of Sac-TMT combined with KL-A167 as neoadjuvant treatment for triple-negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SKB264 — 1\) Neoadjuvant Treatment Phase Phase a: All eligible subjects will receive Sac-TMT (5 mg/kg, Day 1, every 2 weeks) combined with KL-A167 (900 mg, Day 1, every 2 weeks) for 6 cycles (12 weeks). At Week 12 (beginning of Week 13), radiographic assessment via contrast-enhanced breast MRI will be performed. Based on tumor response, patients proceed to Neoadjuvant Phase b: i. Responders (investigator-assessed Partial Response \[PR\] or Complete Response \[CR\]): Continue the same combination regimen for an additional 12 weeks of neoadjuvant therapy. ii. Non-responders (investigator-assessed Stable Disease \[SD\] or Progressive Disease \[PD\]): Switch to KL-A167 (900 mg every 2 weeks) combined with nab-paclitaxel (100 mg/m², Days 1, 8, 15, every 4 weeks per cycle) and carboplatin (AUC 2 mg·min/mL, Days 1, 8, 15, every 4 weeks per cycle) for 12 weeks.

Primary Outcomes

  • pCR (after neoadjuvant treatment, at surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-24
Completion: 2030-08
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Jiao Tong University School of Medicine
Contact Information
Study Contact:
Xiaosong Chen
+86-21-64370045-602102
chenxiaosong0156@hotmail.com
Xiaosong Chen
+86-21-64370045-602102
xiaosongchen0156@hotmail.com
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
Interventions
  • Drug: SKB264 — 1\) Neoadjuvant Treatment Phase Phase a: All eligible subjects will receive Sac-TMT (5 mg/kg, Day 1, every 2 weeks) combined with KL-A167 (900 mg, Day 1, every 2 weeks) for 6 cycles (12 weeks). At Week 12 (beginning of Week 13), radiographic assessment via contrast-enhanced breast MRI will be performed. Based on tumor response, patients proceed to Neoadjuvant Phase b: i. Responders (investigator-assessed Partial Response \[PR\] or Complete Response \[CR\]): Continue the same combination regimen for an additional 12 weeks of neoadjuvant therapy. ii. Non-responders (investigator-assessed Stable Disease \[SD\] or Progressive Disease \[PD\]): Switch to KL-A167 (900 mg every 2 weeks) combined with nab-paclitaxel (100 mg/m², Days 1, 8, 15, every 4 weeks per cycle) and carboplatin (AUC 2 mg·min/mL, Days 1, 8, 15, every 4 weeks per cycle) for 12 weeks.
Study Locations (1 sites)
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital, Shanghai, Shanghai Municipality 200025 China
Eligibility Criteria
Inclusion Criteria: * Age: 18-65 years old. * Diagnosis: Histologically and/or cytologically confirmed primary triple-negative breast cancer (TNBC) (excluding inflammatory breast cancer), meeting the criteria of tumor size ≥2 cm, clinical lymph node stage cN0 to cN3, and M0 (no distant metastasis). TNBC Definition: Immunohistochemistry (IHC) showing ER and PR \<10%; HER2-negative: IHC 0 or 1+, or IHC 2+ with negative in situ hybridization (ISH). * Tissue Sample: Availability of tumor tissue sample for biomarker testing. * Measurable Disease: At least one measurable lesion according to RECIST v1.1 criteria. Lesions previously irradiated cannot be selected as target lesions. Subjects with only skin lesions or bone lesions are excluded. * Performance Status: Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 within 7 days prior to treatment initiation. * Adequate Organ and Bone Marrow Function: Hematology: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count (PLT) ≥ 80 × 10⁹/L; Hemoglobin ≥ 10 g/dL. Liver Function: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × upper limit of normal (ULN); Total bilirubin (TBIL) ≤ 1.5 × ULN. Renal Function: Creatinine clearance (Ccr) ≥ 60 mL/min (calculated using the Cockcroft-Gault formula). Coagulation: International normalized ratio (INR), activated partial thromboplastin time (APTT), and prothrombin time (PT) ≤ 1.5 × ULN. Cardiac Function: Left ventricular ejection fraction (LVEF) ≥ 55% as measured by echocardiography (ECHO) or multigated acquisition (MUGA) scan. * Prior Treatment: No prior anti-tumor therapy for the current breast cancer. * Contraception: Female subjects must have a negative serum pregnancy test. Female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to use highly effective medically approved contraceptive methods from the time of signing the informed consent form until 6 months after the last dose of study drug. * Informed Consent: Patients must voluntarily enroll in the study, provide written informed consent, and be able to comply with the protocol-specified visits and procedures. Exclusion Criteria: * Cardiovascular Disease: Baseline left ventricular ejection fraction (LVEF) \< 55% assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan at screening, or any other significant cardiovascular disease, or myocardial disease classified as New York Heart Association (NYHA) Class III or IV. * Prior Ipsilateral Breast Cancer: History of ipsilateral invasive breast cancer. * Prior Treatment for Current Breast Cancer: Any prior chemotherapy, targeted therapy, and/or radiotherapy for the currently diagnosed breast cancer prior to enrollment. * Prior Immune Checkpoint Inhibitor Therapy: Previous treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. * Prior TROP2/Topo I Inhibitor Therapy: Previous treatment with any TROP2-targeted therapy and/or topoisomerase I inhibitor. * Other Malignancies: History of other active malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin. * Clinically Significant Pulmonary Impairment: Clinically significant pulmonary impairment due to concurrent pulmonary disease, including but not limited to: Any underlying pulmonary disease (e.g., pulmonary embolism within 3 months prior to treatment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.) Any autoimmune, connective tissue, or inflammatory disease with potential pulmonary involvement (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.) * History of pneumonectomy. * CYP3A4 Modulators: Requirement for strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 2 weeks prior to the first dose or during the study period (Concomitant use of strong CYP3A4 inhibitors or inducers is prohibited in this study; representative agents are listed in Appendix 2). All subjects must avoid concomitant use of any known CYP3A4-inducing drugs, herbal supplements, and/or food. * Contraindications/History: Known history of allergy/hypersensitivity to the study drugs or their components; history of immunodeficiency; history of organ transplantation. * Interstitial Lung Disease (ILD)/Pneumonitis: History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring systemic steroid therapy. Current ILD or non-infectious pneumonitis. Suspicious ILD or non-infectious pneumonitis on imaging at screening that cannot be ruled out by imaging evaluation. * Ocular Diseases: Documented severe dry eye syndrome, severe meibomian gland dysfunction and/or blepharitis, or history of corneal disease that may delay corneal epithelial healing. * Active Autoimmune Disease: Active autoimmune disease that has required systemic treatment within the past 2 years (Note: Hormone replacement therapy is not considered systemic treatment; e.g., type I diabetes, hypothyroidism managed with thyroid hormone replacement only, adrenal or pituitary insufficiency managed with physiologic corticosteroid replacement only). * Active Infection: Active infection requiring systemic therapy within 2 weeks prior to the first dose. * Uncontrolled Comorbidities: Any significant concurrent illness, in the investigator's judgment, that may jeopardize patient safety or affect study completion, including but not limited to uncontrolled hypertension, severe diabetes, active infection, etc. * Investigator Discretion: Any condition that, in the investigator's opinion, could interfere with the evaluation of the study drug, compromise patient safety, or interpretation of study results, or any other condition that makes the subject unsuitable for study participation.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 126
Locations 58 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Proportion of patients who receive Olaparib for the full treatment duration (18 months after inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-30
Completion: 2028-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
N/A
Study Locations (58 sites)
Research Site, Clermont-Ferrand, Auvergne-Rh ne-Alpes 63050 France
Research Site, Gleizé, Auvergne-Rh ne-Alpes 69400 France
Research Site, Grenoble, Auvergne-Rh ne-Alpes 38000 France
Research Site, Lyon, Auvergne-Rh ne-Alpes 69317 France
Research Site, Metz-Tessy, Auvergne-Rh ne-Alpes 74370 France
Research Site, Saint-Etienne, Auvergne-Rh ne-Alpes 42030 France
Research Site, Saint-Priest-en-Jarez, Auvergne-Rh ne-Alpes 42271 France
Research Site, Thonon-les-Bains, Auvergne-Rh ne-Alpes 74200 France
Research Site, Valence, Auvergne-Rh ne-Alpes 26000 France
Research Site, Valence, Auvergne-Rh ne-Alpes 26953 France
Eligibility Criteria
Inclusion Criteria: * Male or female aged ≥ 18 years * Patient diagnosed with HER2-negative eBC * Patient about to be initiated with adjuvant Olaparib at their physician's discretion * Patient has been informed and does not object to participation in the study. Exclusion Criteria: * Patient not consenting to participate. * Patients included in the Early Access Program

CAIX-targeted PET/CT in Solid Tumors

NCT07833085
Recruiting
Conditions Malignant Solid Tumors, Clear Cell Renal...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 68Ga-CAIX — The subjects receive a PET/CT scan 30-60 minutes after intravenous administration of 68Ga-CAIX

Primary Outcomes

  • Evaluation of diagnostic performance (up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-21
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhongnan Hospital
Principal Investigators:
  • Yong He, MD, PhD (PRINCIPAL_INVESTIGATOR) - Zhongnan Hospital
Contact Information
Study Contact:
Chongjiao Li, MD, PhD
+86-27-67812698
LCJ0301@163.com
Lei Zheng, PhD
+86-27-67812787
znyyll@126.com
Zhongnan hospital of Wuhan University
Interventions
  • Diagnostic Test: 68Ga-CAIX — The subjects receive a PET/CT scan 30-60 minutes after intravenous administration of 68Ga-CAIX
Study Locations (1 sites)
Zhongnan hospital of Wuhan University, Wuhan, Hubei 430071 China
Eligibility Criteria
Inclusion Criteria: * Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology; * Age of 18 years and above, both male and female are eligible; * The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points; * Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol. Exclusion Criteria: * Participants with severe liver and kidney dysfunction and cardiac dysfunction; * Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans; * Pregnant or lactating women; * Other situations that researchers believe should be excluded and documented.
Conditions Breast Cancer, Non-small Cell Lung Cance...
Phase PHASE1
Enrollment 156
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of \[177Lu\]Lu-DWJ155 and the safety and imaging properties of \[68Ga\]Ga-DWJ155 in patients with histologically or cytologically confirmed advanced HER2+, HR+/HER2-negative, or triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), HER2-3+ or 2+ (ISH positive or negative) gastric/gastroesophageal junction (GEJ) cancer, and bladder cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: [68Ga]Ga-DWJ155 — Radioligand imaging agent
  • Drug: [177Lu]Lu-DWJ155 — Radioligand therapy

Primary Outcomes

  • Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) of [177Lu]Lu-DWJ155 (Up to approximately 53 months)
  • Incidence of dose-limiting toxicities (DLTs) of [177Lu]Lu-DWJ155 (Up to 6 weeks)
  • Frequency of dose interruptions and reductions [177Lu]Lu-DWJ155 (11 months)
  • Dose intensity [177Lu]Lu-DWJ155 (11 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-16
Completion: 2032-05-24
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
1-888-669-6682
novartis.email@novartis.com
Novartis Pharmaceuticals
+41613241111
Marlene Bridwell
+1 402 691 6972
mbridwell@nebraskacancer.com
Nebraska Cancer Specialists
Interventions
  • Diagnostic Test: [68Ga]Ga-DWJ155 — Radioligand imaging agent
  • Drug: [177Lu]Lu-DWJ155 — Radioligand therapy
Study Locations (5 sites)
Nebraska Cancer Specialists, Omaha, Nebraska 68130 United States
Novartis Investigative Site, Darlinghurst, New South Wales 2010 Australia
Novartis Investigative Site, Montreal, Quebec H2X 0A9 Canada
Novartis Investigative Site, Montreal, Quebec H4A 3J1 Canada
Novartis Investigative Site, Kashiwa, Chiba 2778577 Japan
Eligibility Criteria
Inclusion Criteria: * Male or female patients age ≥ 18 years. * Patients with one of the following histologically or cytologically confirmed and documented malignancies who have progressed on or been intolerant to standard of care therapy, and are not considered appropriate for any standard therapy with proven benefit, in the investigator's judgment: * Dose Escalation: * Advanced HER2+ breast cancer with disease progression after at least two prior lines of systemic therapy in the advanced setting * Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting * Advanced NSCLC without actionable genetic alterations (AGAs) with disease progression after prior therapy in the advanced setting * Advanced NSCLC with AGAs who have received prior treatment * Measurable disease as determined by RECIST version 1.1. * Dose Expansion: * Advanced HER2+ breast cancer with disease progression after at least two prior lines of systemic therapy in the advanced setting * Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting * Advanced HR+/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting * Advanced HR-/HER2-low breast cancer with disease progression after prior therapy in the advanced setting * Advanced HR-/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting * Advanced NSCLC with AGAs, who have received prior treatment * Advanced NSCLC without known AGAs who have received prior treatment. * Advanced gastric/GEJ cancer with HER2 IHC 3+ or 2+ (ISH + or -), following disease progression after prior therapy in the advanced setting * Advanced bladder cancer following disease progression after prior therapy in the advanced setting * Measurable disease as determined by RECIST version 1.1. Exclusion Criteria: * Out-of-range laboratory values defined as: * Creatinine clearance \< 60 mL/min (calculated using CKD-EPI 2021 formula, or measured) * Total bilirubin \> 1.5 x ULN (except for patients with Gilbert's syndrome who are excluded if total bilirubin \>3.0 x ULN) or direct bilirubin \> 1.5 x ULN * Alanine aminotransferase (ALT) \> 3 x ULN, except for patients with tumor involvement of the liver who are excluded if ALT \> 5 x ULN * Aspartate aminotransferase (AST) \> 3 x ULN, except for patients with tumor involvement of the liver who are excluded if AST \> 5 x ULN * Lipase \> 1.5 x ULN * Absolute neutrophil count (ANC) \< 1.5 x 109/L * Hemoglobin \< 9 g/dL * Platelet count \< 100 x 109/L * Initiation of hematopoietic colony stimulating factors, thrombopoietin mimetics, or erythroid stimulating agents initiated ≤ 2 weeks prior to imaging agent administration. * Use of transfusion support ≤4 weeks prior to imaging agent administration. * Impaired cardiac function or clinically significant cardiac disease. * Unmanageable urinary tract obstruction or urinary incontinence. * Any serious uncontrolled infection (acute or chronic). * Pregnant or breastfeeding women. * Treatment with any of the following anti-cancer therapies prior to imaging agent administration within the stated timeframes: * Prior treatment with any therapeutic radiopharmaceutical * \< 10 half-lives for any imaging radiopharmaceutical * ≤ 4 weeks for external beam radiation therapy (EBRT) or brachytherapy * ≤ 6 months for lung-directed external beam radiotherapy * Patients with non-tumor uptake of \[68Ga\]Ga-DWJ155 in tissues or organs that, in the opinion of the investigator, increases the risk associated with \[177Lu\]Lu-DWJ155 treatment. Other protocol-defined inclusion/exclusion criteria may apply.
Conditions Sentinel Lymph Node Biopsy
Phase Not Applicable
Enrollment 508
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

SLNB has been recommended by domestic and foreign guidelines for patients with initial cN1 and NAC descending to ycN0. However, the best technical path is still not very clear at present, and the long-term tumor safety data is still insufficient. Therefore, it is necessary to further explore the optimal technical pathway and long-term tumor safety for SLNB in patients with initial cN1 and NAC downgrading to ycN0 in the real world.This study will evaluate the optimized technical pathway and long-term tumor safety of SLNB in patients with initial cN1 and NAC downgrading to ycN0 in real-world studies.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Other: SLNB group — After the completion of neoadjuvant therapy, axillary SLNB should be performed first before breast surgery; If the frozen pathology SLNs are negative, ALND will no longer be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If frozen pathology is false negative.

Primary Outcomes

  • Axillary recurrence-free survival (5th year after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-30
Completion: 2028-03-31
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 508 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Principal Investigators:
  • Zhenzhen Liu (PRINCIPAL_INVESTIGATOR) - Henan Cancer Hospital
Contact Information
Study Contact:
Zhenzhen Liu
0371-65587005
liuzhenzhen73@126.com
Minhao Lv
0371-65587406
Liu Zhen
13838308034
Henan cacer hospital
Interventions
  • Other: SLNB group — After the completion of neoadjuvant therapy, axillary SLNB should be performed first before breast surgery; If the frozen pathology SLNs are negative, ALND will no longer be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If frozen pathology is false negative.
Study Locations (1 sites)
Henan cacer hospital, Henan, Henan 450008 China
Eligibility Criteria
Inclusion Criteria: 1. Patients With ECOG Score 0-1 Points 2. Patients With Breast Cancer Stage cT1-3N1M0 (According to AJCC Version 7) Pathological Diagnosis of Ipsilateral Axillary Lymph Node Metastasis in Patients With Invasive Breast Cancer 3. Patients With Abnormal Axillary Lymph Nodes ≤ 3 Detected by Imaging Examination 4. Patients With Effective Neoadjuvant Therapy (CR+PR) 5. Patients With Clinical Axillary Negative ycN0 After Neoadjuvant Therapy 6. Patients Without Prior History of Ipsilateral Axillary Surgery and Radiation Therapy 7. Patients Without Previous History of Ipsilateral Breast Cancer (Including Carcinoma in Situ) 8. Patients Without Obvious Contraindications for Surgery or Radiation Therapy 9. No Other History of Malignant Tumors Within 5 Years From Enrollment in the Study 10. Patients Who Participate in Other Clinical Trials at the Same Time and Are Judged by the Researchers Not to Affect the Study Protocol Can be Enrolled Normally 11. The patient voluntarily joined this study and signed an informed consent form. Exclusion Criteria: 1. Stage IV (metastatic) breast cancer; 2. Simultaneous double breast cancer; 3. Baseline cT4; 4. Baseline cN2-3 5. gestation 6. There are contraindications for SLNB; 7. Suffering from serious comorbidities or other comorbidities that may interfere with the planned treatment, or any other circumstances in which the researcher deems the patient unsuitable to participate in this study
Conditions Breast Cancer, TNBC - Triple-Negative Br...
Phase Not Applicable
Enrollment 900
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working. Ultimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: There are no interventions in this observational study. — There are no interventions in this observational study.

Primary Outcomes

  • Invasive Disease-Free Survival (iDFS) stratified by MRD status during neoadjuvant, post-surgery landmark, post definitive treatment (surveillance), and long-term follow-up (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-27
Completion: 2033-12
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tempus AI
Principal Investigators:
  • Michelle Ting-Lin, MD (PRINCIPAL_INVESTIGATOR) - Tempus AI
Contact Information
Study Contact:
GEMINI Breast Clinical Study Manager
(833) 514-4187
gemini-breast@tempus.com
Amanda Joseph
Amanda.Joseph@alabamaoncology.com
Birmingham Hematology Associates
Matthew Tucker
Birmingham Hematology Associates
Interventions
  • Other: There are no interventions in this observational study. — There are no interventions in this observational study.
Study Locations (16 sites)
Birmingham Hematology Associates, Birmingham, Alabama 35223 United States
PIH Health Whittier Hospital, Whittier, California 90602 United States
Cleveland Clinic Florida, Weston, Florida 33331 United States
Southern Illinois Hospital Services, Carbondale, Illinois 62902 United States
Cancer Care Specialist of Illinois, O'Fallon, Illinois 62269 United States
Goshen Center for Cancer Care, Goshen, Indiana 46526 United States
Trinity Health, Ann Arbor, Michigan 48106 United States
Oncology Hematology Associates, Springfield, Missouri 65807 United States
Cancer Care Specialist of Reno, Reno, Nevada 89511 United States
Summit Medical Group, Florham Park, New Jersey 07932 United States
Eligibility Criteria
Inclusion Criteria: All Cohorts: 1. Willing and able to participate in the research and provide biospecimens 2. Willing and able to provide informed consent 3. Must be diagnosed with breast cancer Cohort 1: Neoadjuvant Treatment Cohort 1A: Newly Diagnosed, High Risk HR+,HER2- 1. A known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III disease) 2. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger. Cohort 1B: HER2+ 1. A known or suspected HER2+ breast cancer treated with curative intent (Stage II to III disease). Inclusive of HR+ or HR- patients. Cohort 1C: Triple Negative Breast Cancer 1\. A known or suspected triple negative breast cancer treated with curative intent (Stage I to III disease). Cohort 2: Adjuvant Therapy / Surveillance Cohort 2A: Newly Diagnosed HR+,HER2- 1. A known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III disease) 2. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger. 3. Have undergone curative intent surgery with no clinical evidence of disease. Cohort 2B: HER2+ 1. A known or suspected HER2+ breast cancer treated with curative intent (Stage II to III disease) 2. Have undergone curative intent surgery with no clinical evidence of disease. Cohort 2C: Triple Negative Breast Cancer 1. A known or suspected triple negative breast cancer treated with curative intent (Stage I to III disease) 2. Have undergone curative intent surgery with no clinical evidence of disease. Cohort 3: 5-Years Post-Diagnosis Surveillance (NED) 1. A known HR+, HER2- breast cancer treated with curative intent (Stage II to III disease). 2. No Evidence of Disease (NED) ≥ 5 years from initial diagnosis. 3. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger. Exclusion Criteria: 1. Not willing or able to adhere with the study procedures 2. Active secondary malignancy 3. Diagnosis of a malignancy within 3 years of breast cancer diagnosis Note: Ductal carcinoma in situ (DCIS, ipsilateral or contralateral) within 3 years is not excluded.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

CANDY is a single-center, prospective study designed to observe the evolution of clinical and motivational constructs during the APA program KHEOPS program, already offered to patients at the Centre Léon Bérard (CLB). The main aim of the CANDY study is to observe the evolution of psychological constructs derived from M-PAC during a 13-week KHEOPS APA program in women undergoing treatment for breast cancer. Secondary objectives are: * to examine the feasibility of psychological measures and participation in the KHEOPS program * to observe cancer-related psychological symptoms during the KHEOPS program and to investigate the links between the temporal evolution of psychological factors (clinical and motivational) and adherence to the KHEOPS program, as well as the level of post-program PA during and after the KHEOPS program in patients followed at the CLB.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Behavioral: KHEOPS program — the KHEOPS program is an physical activity intervention, offered to patients

Primary Outcomes

  • score for each construct of multiprocess action control model (M-PAC) (Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), one friday per month (Friday week 1 to Friday week 22), post-intervention + 1 month (Week 26))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-18
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Leon Berard
Collaborators: Cancéropôle Lyon Auvergne Rhône-Alpes
Principal Investigators:
  • Olivia Perol, PhD (STUDY_DIRECTOR) - Département Prévention Cancer Environnement, Centre Léon Bérard
  • Béatrice Fervers, Pr (PRINCIPAL_INVESTIGATOR) - Département Prévention Cancer Environnement, Centre Léon Bérard
  • Johan Caudroit, PhD (STUDY_DIRECTOR) - Université Lyon1
Contact Information
Study Contact:
Carmen Dupuis, PhD
0469856218
carmen.dupuisl@lyon.unicancer.fr
Carmen Dupuis, PhD
0469856218
carmen.dupuis@lyon.unicancer.fr
Centre Léon Bérard
Béatrice Fervers, Pr
Centre Léon Bérard
Interventions
  • Behavioral: KHEOPS program — the KHEOPS program is an physical activity intervention, offered to patients
Study Locations (1 sites)
Centre Léon Bérard, Lyon, 69373 France
Eligibility Criteria
Inclusion Criteria * Woman aged ≥ 18 years * Diagnosed with non-metastatic breast cancer * Undergoing treatment or after surgery * Participating in the CLB KHEOPS program, either face-to-face or distance learning * Have a smartphone, computer or tablet to answer the 2 weekly online weekly online questionnaires and to follow APA sessions for patients following the patients following the KHEOPS program remotely * Having received a study information note and having made a declaration of non-opposition * Affiliated with a social security scheme * Able to read, write and understand French Exclusion Criteria: * Unable to be followed for medical, social, family, geographical or psychological reasons, for the duration of the study. * Have difficulty completing a questionnaire alone * Deprived of liberty by judicial or administrative decision, or adults protected by law * Concurrently participating in another PA study
Conditions Breast Cancer, Cardiovascular Diseases
Phase NA
Enrollment 260
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This is a feasibility study employing virtual patient navigation for underserved individuals who speak English, Chinese or Spanish and were diagnosed with breast cancer or cardiovascular disease to determine the extent of usability for a virtual patient navigation portal serving people in underserved communities. While not able to entirely replace in-person interactions, virtual patient navigation may be used to expand reach and availability of navigation services to a much greater segment of the population.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Patient Navigation Program — Online health tool
  • Other: Quality-of-Life (QOL) Assessment — Online surveys to assess QOL
  • Other: Survey Administration — Ancillary studies

Primary Outcomes

  • Proportion of participants who reported satisfaction with COUNTS program (Up to 6 months)
  • Rate of Participation (Up to 6 months)
  • Utilization rate (Up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-10
Completion: 2027-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Principal Investigators:
  • Scarlett L Gomez, PhD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Laura Allen
415-818-7143
Laura.Allen@ucsf.edu
Laura Allen
415-818-7143
Laura.Allen@ucsf.edu
Zuckerberg San Francisco General Hospital
Laura Allen
415-818-7143
Laura.Allen@ucsf.edu
University of California, San Francisco
Interventions
  • Behavioral: Patient Navigation Program — Online health tool
  • Other: Quality-of-Life (QOL) Assessment — Online surveys to assess QOL
  • Other: Survey Administration — Ancillary studies
Study Locations (2 sites)
Zuckerberg San Francisco General Hospital, San Francisco, California 94110 United States
University of California, San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: For Focus groups: * Breast cancer patients: Diagnosed with breast cancer, ages 18 or older, speaks English, Mandarin/Cantonese, or Spanish * Navigators: any patient navigator who has provided care to underserved populations diagnosed with cancer For Portal Implementation phase: * Ages 18 or older * Speaks English, Mandarin/Cantonese, Spanish, * Has any stage breast cancer * Has access to a phone that is able to receive text messages, is willing to stay in the study for six-seven months. Family User experience survey: * Family member or friend who may have assisted breast cancer participant with registration, accessing or otherwise assisting breast cancer family member or friend participant with the online portal. Exclusion Criteria: * Any medical or psychological conditions precluding informed consent
Conditions Breast Cancer
Phase Not Applicable
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study is an investigator-initiated, single-arm, single-center, prospective, observational study. The hypothesis is that during the implementation of deep inspiration breath-hold (DIBH) radiotherapy plans in postoperative breast cancer patients receiving internal mammary irradiation, the actual target dose coverage and organ-at-risk (OARs) dose parameters remain within clinically acceptable ranges.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Radiation: DIBH with 3mm Gating Window — The patient will receive moderately hypofractionated radiotherapy targeting the ipsilateral breast, supraclavicular and internal mammary nodes, and high-risk axillary region, with a prescribed dose of 40 Gy (RBE) /15Fx. IMRT, VMAT, or proton therapy will be chosen based on the radiation oncologist's judgment and patient preference. Respiratory gating tolerance is set at ±1.5 mm (3 mm total). Three simulated CT scans during DIBH will assess gating window positions: CT1: Breath-hold at the center of the gating window. CT2: Breath-hold at the upper edge, simulating maximum thoracic expansion. CT3: Breath-hold at the lower edge, simulating minimum thoracic expansion. Setup errors (intrafraction and interfraction) and respiratory waveforms monitored via Surface Guided Radiation Therapy(SGRT)systems will be recorded for analysis.
  • Radiation: DIBH with 2 mm Gating Window — The patient will receive moderately hypofractionated radiotherapy targeting the ipsilateral breast, supraclavicular and internal mammary nodes, and high-risk axillary region, with a prescribed dose of 40 Gy (RBE) /15Fx. IMRT, VMAT, or proton therapy will be chosen based on the radiation oncologist's judgment and patient preference. Respiratory gating tolerance is set at ±1 mm (2 mm total). Three simulated CT scans during DIBH will assess gating window positions: CT1: Breath-hold at the center of the gating window. CT2: Breath-hold at the upper edge, simulating maximum thoracic expansion. CT3: Breath-hold at the lower edge, simulating minimum thoracic expansion. Setup errors (intrafraction and interfraction) and respiratory waveforms monitored via SGRT systems will be recorded for analysis.
  • Radiation: DIBH with 1.5 mm Gating Window — The patient will receive moderately hypofractionated radiotherapy targeting the ipsilateral breast, supraclavicular and internal mammary nodes, and high-risk axillary region, with a prescribed dose of 40 Gy (RBE) /15Fx. IMRT, VMAT, or proton therapy will be chosen based on the radiation oncologist's judgment and patient preference. Respiratory gating tolerance is set at ± 0.75 mm (1.5 mm total). Three simulated CT scans during DIBH will assess gating window positions: CT1: Breath-hold at the center of the gating window. CT2: Breath-hold at the upper edge, simulating maximum thoracic expansion. CT3: Breath-hold at the lower edge, simulating minimum thoracic expansion. Setup errors (intrafraction and interfraction) and respiratory waveforms monitored via SGRT systems will be recorded for analysis.

Primary Outcomes

  • Target coverage of the Planning treatment volume (PTV) (Upon completion of radiotherapy treatment planning, prior to the first fraction of treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-01
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ruijin Hospital
Contact Information
Study Contact:
Lu Cao, PhD
+86-021-64370045
cl11879@rjh.com.cn
Lu Cao, PhD
86-021-64370045
cl11879@rjh.com.cn
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Interventions
  • Radiation: DIBH with 3mm Gating Window — The patient will receive moderately hypofractionated radiotherapy targeting the ipsilateral breast, supraclavicular and internal mammary nodes, and high-risk axillary region, with a prescribed dose of 40 Gy (RBE) /15Fx. IMRT, VMAT, or proton therapy will be chosen based on the radiation oncologist's judgment and patient preference. Respiratory gating tolerance is set at ±1.5 mm (3 mm total). Three simulated CT scans during DIBH will assess gating window positions: CT1: Breath-hold at the center of the gating window. CT2: Breath-hold at the upper edge, simulating maximum thoracic expansion. CT3: Breath-hold at the lower edge, simulating minimum thoracic expansion. Setup errors (intrafraction and interfraction) and respiratory waveforms monitored via Surface Guided Radiation Therapy(SGRT)systems will be recorded for analysis.
  • Radiation: DIBH with 2 mm Gating Window — The patient will receive moderately hypofractionated radiotherapy targeting the ipsilateral breast, supraclavicular and internal mammary nodes, and high-risk axillary region, with a prescribed dose of 40 Gy (RBE) /15Fx. IMRT, VMAT, or proton therapy will be chosen based on the radiation oncologist's judgment and patient preference. Respiratory gating tolerance is set at ±1 mm (2 mm total). Three simulated CT scans during DIBH will assess gating window positions: CT1: Breath-hold at the center of the gating window. CT2: Breath-hold at the upper edge, simulating maximum thoracic expansion. CT3: Breath-hold at the lower edge, simulating minimum thoracic expansion. Setup errors (intrafraction and interfraction) and respiratory waveforms monitored via SGRT systems will be recorded for analysis.
  • Radiation: DIBH with 1.5 mm Gating Window — The patient will receive moderately hypofractionated radiotherapy targeting the ipsilateral breast, supraclavicular and internal mammary nodes, and high-risk axillary region, with a prescribed dose of 40 Gy (RBE) /15Fx. IMRT, VMAT, or proton therapy will be chosen based on the radiation oncologist's judgment and patient preference. Respiratory gating tolerance is set at ± 0.75 mm (1.5 mm total). Three simulated CT scans during DIBH will assess gating window positions: CT1: Breath-hold at the center of the gating window. CT2: Breath-hold at the upper edge, simulating maximum thoracic expansion. CT3: Breath-hold at the lower edge, simulating minimum thoracic expansion. Setup errors (intrafraction and interfraction) and respiratory waveforms monitored via SGRT systems will be recorded for analysis.
Study Locations (1 sites)
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality 200025 China
Eligibility Criteria
Inclusion Criteria: 1. Provide a signed and dated informed consent form (ICF) before the initiation of any trial-specific procedures. 2. Female patients aged ≥ 18 years. 3. Histologically confirmed invasive breast cancer. 4. Have received breast-conserving surgery or mastectomy with axillary staging, including sentinel lymph node biopsy and/or axillary lymph node dissection. 5. Able to hold breath for more than 30 seconds after deep inspiration. 6. Planned to receive postoperative radiotherapy targeting regional lymph nodes, including the internal mammary nodes, under DIBH conditions. 7. Planned to undergo moderate hypofractionated radiotherapy. 8. Karnofsky Performance Status (KPS) score ≥ 80. 9. The estimated life expectancy of greater than 5 years . 10. Sufficient wound healing from surgery, with no signs of active infection at the intended radiation site. Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Presence of any severe, uncontrolled comorbidity or medical condition that, in the investigator's judgment, would render the participant unsuitable for the study, compromise protocol compliance, or confound the interpretation of study results. 3. Unable to understand or comply with breath-hold training instructions. 4. Right-sided breast cancer.
Conditions Metastatic Breast Cancer
Phase Not Applicable
Enrollment 150
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Ample evidence has highlighted the significant clinical benefit of novel therapies for many patients with advanced breast cancer (aBC). The use of CDK inhibitors, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and PARP inhibitors as first-line or subsequent treatments has improved progression-free survival (PFS) rates compared to conventional therapies. In selected cases, these treatments have also increased overall survival (OS), reshaping the therapeutic landscape for advanced breast cancer. However, several key questions remain unanswered. For example, what should be the first-line treatment when multiple effective options are available? Determining the optimal sequence of drugs in successive lines of therapy is another major challenge. Furthermore, the development of resistance to treatment and the occurrence of severe adverse events that may lead to early discontinuation or fatal outcomes are pressing concerns. That said, identifying robust predictive biomarkers of response or resistance is crucial for ensuring that patients receive the most effective treatment while avoiding unnecessary exposure to therapies that could cause harm without benefit. Additionally, when multiple effective options exist, selecting the optimal treatment algorithm for each patient based on clinical, pathological, and molecular biomarkers is essential. We herein, aim at employing high throughput methodologies, such as Whole Exome Sequencing, circulating tumour DNA (ctDNA) analysis, digital pathology and radiomics analyses, as well as real-world data obtained both from patients records for the training of a ML-based algorithm that can predict response or resistance to a specific treatment, based on the genetic make-up of the patient and the molecular profile of the tumour.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Progression-free survival (PFS) (Through study completion, 5 years)
  • Overall Survival (OS) (Through study completion, 5 years)
  • Objective Response Rate (ORR) (Through study completion, 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-15
Completion: 2029-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hellenic Cooperative Oncology Group
Principal Investigators:
  • Elena Fountzilas, MD, PhD (PRINCIPAL_INVESTIGATOR) - Hellenic Cooperative Oncology Group
Contact Information
Study Contact:
Electra Sofou, PhD
+302106912520
e_sofou@hecog.ondsl.gr
Elena Fountzilas, MD, PhD
+302106912520
elenafou@gmail.com
Georgia Gomatou, MD, PhD
+306973598542
georgiagom@med.uoa.gr
University General Hospital "ATTIKON", 2nd propedeutic dept. of Internal Medicine
Interventions
N/A
Study Locations (5 sites)
University General Hospital "ATTIKON", 2nd propedeutic dept. of Internal Medicine, Athens, GR 12462 Greece
"MITERA" Hospital, Dept. of Medical Oncology, Athens, GR 15123 Greece
Metropolitan Hospital, 2nd Dept. of Medical Oncology, Athens, GR 18547 Greece
Metropolitan Hospital, 4th Dept. of Medical Oncology, Athens, GR 18547 Greece
St. Luke's Hospital, Dept. of Medical Oncology, Thessaloniki, GR 55236 Greece
Eligibility Criteria
Inclusion Criteria: * Eligible patients will be 18 years of age and older * Histologically confirmed, advanced breast cancer. * Diagnosis of i) hormone receptor positive and/or ii) HER2-positive or -low or iii) triple negative breast cancer (TNBC). * Patients will be included in the analysis after receiving at least one treatment cycle. Exclusion Criteria: * Diagnosis of early breast cancer at time of enrollment * Unwillingness to provide informed consent * Unwillingness to provide biological specimen * Lack of comprehensive clinical data